Mostrar el registro sencillo del ítem

dc.contributor.authorCarrillo, Paloma
dc.contributor.authorOcaña, Mª Carmen
dc.contributor.authorMartínez-Poveda, Beatriz
dc.contributor.authorMedina, Miguel Ángel 
dc.contributor.authorQuesada, Ana R.
dc.date.accessioned2017-07-21T07:25:16Z
dc.date.available2017-07-21T07:25:16Z
dc.date.created2017
dc.date.issued2017-07-21
dc.identifier.urihttp://hdl.handle.net/10630/14305
dc.description.abstractThe inhibition of angiogenesis has attracted broad attention in the field of pharmacological research, not only for cancer, but for other angiogenesis dependent diseases including ophthalmic, cutaneous and inflammatory diseases, as well as a number of rare diseases. Our research group has characterized multiple new natural bioactive compounds with multitargeted antiangiogenic effects by employing a well-established set of in vitro, in vivo and ex vivo preclinical models of angiogenesis. Most of them have been isolated from plants and terrestrial microorganisms, mainly due to their higher availability and because their therapeutic effects had been previously known in folk traditional medicines. In vitro primary screening includes cell differentiation and toxicity and proliferation assays. Secondary screening involves several experiments to evaluate effects on adhesion, migration, invasion, apoptosis or cell cycle analysis, among others. Additionally, we perform a further molecular characterization analyzing possible signaling pathways that are affected to elucidate their mechanism of action. The characterization is completed with the ex vivo aortic ring assay, and in vivo assays, as CAM and zebrafish assays, to ensure the anti-angiogenic ability. As a fruit of the mentioned screening, a number of compounds with remarkable anti-angiogenic activity have been identified and characterized.es_ES
dc.description.sponsorshipOur experimental work is supported by grants BIO2014-56092-R (MINECO and FEDER) and P12-CTS-1507 (Andalusian Government and FEDER) and funds from group BIO-267 (Andalusian Government). The "CIBER de Enfermedades Raras" is an initiative from the ISCIII (Spain)]. This communicaction has the support of a travel grant "Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech".es_ES
dc.language.isoenges_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectNeovascularizaciónes_ES
dc.subject.otherAngiogenesises_ES
dc.subject.otherNatural bio-active compoundses_ES
dc.titleIdentification and characterization of new anti-angiogenic compounds from natural sourceses_ES
dc.typeinfo:eu-repo/semantics/conferenceObjectes_ES
dc.centroFacultad de Cienciases_ES
dc.relation.eventtitle29th Pezcoller Symposiumes_ES
dc.relation.eventplaceTrento, Italiaes_ES
dc.relation.eventdate22 de junio de 2017es_ES
dc.identifier.orcidhttp://orcid.org/000-0001-7275-6462es_ES
dc.cclicenseby-nc-ndes_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem